Manufacturing roundup: Quality issues at Sun Pharma plant in India; Forge secures gene therapy manufacturing contract
The FDA has revealed further issues at a Sun Pharma manufacturing facility in India.
Last month, Sun Pharma announced it was pausing production at one of its plants in Mohali, India, after facing scrutiny by US regulators over necessary corrective work. US regulators ultimately conveyed to the company that it needs to take corrective actions at the manufacturing facility before it can ship any products to the US.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters